港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

恆瑞醫藥

55.150

+11.10025.20%

成交量：8,266.38萬

成交額：47.34億

市值：3,641.84億

市盈率：53.23

高：60.500

開：57.000

低：55.150

收：44.050

資料載入中...

總覽公司新聞公告

恆瑞醫藥港股上市首日高開近三成，資本加碼助力加速國際化

赴港上市掀起高潮！年內第4只“AH”股誕生

东方财富研究中心

恆瑞醫藥今日在港上市邁入“A+H”雙平臺時代

中國“藥王”登岸香江，募資近百億

恆瑞醫藥副董事長戴洪斌：登陸港股是公司加速創新國際化的關鍵一步

恆瑞醫藥在港上市敲鐘，全球化拓展加速

国际金融报

中信證券助力恆瑞醫藥完成2021年以來港股醫療健康行業最大規模IPO

中信里昂 CITIC CLSA

漲30%，恆瑞醫藥登陸港交所

恆瑞醫藥H股5月23日掛牌上市

【矚目】恆瑞拿下重磅1類新藥，超600億市場波瀾再起

恆瑞新起點

30CM暴漲！41萬股民哭暈，3600億元大白馬，徹底殺瘋了！

恆瑞創今年醫藥IPO紀錄，三生刷新對外授權首付款紀錄，麗珠“出手”越南，中國醫藥出海大潮開啓？

3500億市值藥企赴港敲鐘，折價發行半日股價漲超30%

恆瑞醫藥港股上市首日漲25.2% 募資淨額97.47億港元

中国经济网

創新藥收入持續提升恆瑞醫藥登陸港交所

经济参考网

港股近五年最大醫藥IPO來了！恆瑞醫藥上市首日收漲超25%

恆瑞醫藥在港上市，首日開盤價較發行價上漲29.4%

港股綜述｜恆瑞醫藥首日飆漲25%，Mirxes漲28%；阿里影業漲超8%，港股三大股指衝高回落

老虎资讯综合

年內最強！最慘板塊終於熬出頭了

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":55.15,"timestamp":1747987708026,"preClose":44.05,"halted":0,"volume":82663811,"delay":0,"floatShares":224519800,"shares":6603522074,"eps":1.036,"marketStatus":"未開盤","change":11.1,"latestTime":"05-23 16:08:28","open":57,"high":60.5,"low":55.15,"amount":4733500812,"amplitude":0.121453,"askPrice":55.5,"askSize":2200,"bidPrice":55.15,"bidSize":14200,"shortable":0,"etf":0,"ttmEps":1.036205539,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1748223000000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":44.05,"dividendRate":0.003941,"openAndCloseTimeList":[[1747963800000,1747972800000],[1747976400000,1747987200000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":54.5,"timestamp":1747983600000,"preClose":55.4,"halted":0,"volume":54184000,"delay":0,"premium":"-7.32"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":224519800,"roa":"8.99%","roe":"15.22%","lyrEps":1.036,"shares":6603522074,"dividePrice":0.218371,"high":60.5,"amplitude":0.121453,"preClose":44.05,"low":55.15,"week52Low":55.15,"pbRate":"7.10","psRate":"11.43","week52High":60.5,"institutionHeld":0,"latestPrice":55.15,"committee":0.731707,"eps":1.036,"divideRate":0.00396,"volume":82663811,"delay":0,"ttmEps":1.036205539,"open":57,"prevYearClose":44.05,"prevWeekClose":55.15,"prevMonthClose":44.05,"prevQuarterClose":44.05,"fiveDayClose":44.05,"twentyDayClose":44.05,"sixtyDayClose":44.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537139588","title":"恆瑞醫藥港股上市首日高開近三成，資本加碼助力加速國際化","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139588","media":"观察者网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537139588?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 20:06","pubTimestamp":1748001960,"startTime":"0","endTime":"0","summary":"恒瑞医药此次全球发售H股总数为2.245亿股，发行价定于区间上限44.05港元，募资净额约94.58亿港元。作为国内头部药企，恒瑞医药近年来业绩稳健增长。恒瑞医药的港股上市标志着其全球化布局的重要一步。港股市场汇聚了众多国际投资者，这将有助于恒瑞医药提升国际品牌影响力，优化全球品牌形象。然而，恒瑞医药在国际化进程中仍面临众多挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-05-23/doc-inexqhfw5891885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064131003.USD","LU0405327494.USD","BK0188","LU2148510915.USD","LU2488822045.USD","BK0196","BK0012","BK0060","LU0405327148.USD","LU1328615791.USD","BK0028","HSCEI","LU1064130708.USD","BK4614","01276","BK0183","YANG","600276","BK0239","HSTECH","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":1},{"id":"2537613349","title":"赴港上市掀起高潮！年內第4只“AH”股誕生","url":"https://stock-news.laohu8.com/highlight/detail?id=2537613349","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537613349?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 18:59","pubTimestamp":1747997954,"startTime":"0","endTime":"0","summary":"A股上市公司，正在掀起一波赴港的上市高潮。继宁德时代之后，5月23日（周五），医药巨头恒瑞医药正式登陆港交所，成为年内第4只“AH”股。上市首日，恒瑞医药港股暴涨25.20%，最新总市值达3642亿港元。恒瑞医药能有如此表现的原因或与以下三点有关：一是公司本身质量颇佳；二是2025年以来港股上演了一场“创新药牛市”，港股创新药指数今年涨超30%；三是港股IPO赚钱效应持续凸显，赤峰黄金、钧达股份、宁德时代等上市后股价均有优异表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523190951a48999ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523190951a48999ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","399300","01276","03750","159982"],"gpt_icon":0},{"id":"2537331811","title":"恆瑞醫藥今日在港上市 邁入“A+H”雙平臺時代","url":"https://stock-news.laohu8.com/highlight/detail?id=2537331811","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537331811?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 18:46","pubTimestamp":1747997160,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯 5月23日，恒瑞医药在港交所主板正式挂牌上市，迈入“A+H”双平台时代，并成为近五年港股医药板块最大IPO，也是2025年目前的第二大港股IPO。恒瑞医药此次发行价为44.05港元/股，为发行区间上限定价。近年来，恒瑞医药坚持科技创新和国际化双轮驱动发展战略，业绩稳健增长。研发方面，恒瑞医药累计研发投入达460亿元，在全球设立了14个研发中心，全球研发团队达5500余人。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-23/doc-inexpzxy5997529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064131003.USD","01276","LU1969619763.USD","LU0405327148.USD","BK0012","BK0196","LU0405327494.USD","LU2148510915.USD","BK0028","600276","BK0188","BK0239","LU1064130708.USD","LU1328615791.USD","LU2328871848.SGD","BK0183","LU2488822045.USD","BK0060"],"gpt_icon":0},{"id":"2537138082","title":"中國“藥王”登岸香江，募資近百億","url":"https://stock-news.laohu8.com/highlight/detail?id=2537138082","media":"深蓝财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537138082?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 18:39","pubTimestamp":1747996740,"startTime":"0","endTime":"0","summary":"此次IPO募集资金总额约98.901亿港元，净额约97.473亿港元。恒瑞医药H股股价上市首日暴涨，盘中一度涨至60.50港元，涨幅高达37.34%。此外，恒瑞其他董事及监事合计持股0.1%，其他A股股东持股58.8%，H股股东持股3.4%。5月15日，恒瑞医药在全球发售文件中表示，计划将75%的募资净额用于其研发计划。事实上，恒瑞医药连续多年保持高研发投入，截至今年一季度其累计研发投入已达460亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-23/doc-inexpzxx0698972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","BK1574","HSTECH","BK0060","LU1328615791.USD","GIC","LU2328871848.SGD","LU2148510915.USD","LU1064130708.USD","LU0405327494.USD","LU2488822045.USD","LU1064131003.USD","159982","BK1161","LU1969619763.USD","HSCEI","LU0405327148.USD","BK4614","06978","YANG","399300","BK0012","BK0183","BK0239","600276","01276","BK0188","BK0028","BK4104"],"gpt_icon":1},{"id":"2537918054","title":"恆瑞醫藥副董事長戴洪斌：登陸港股是公司加速創新國際化的關鍵一步","url":"https://stock-news.laohu8.com/highlight/detail?id=2537918054","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537918054?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 18:19","pubTimestamp":1747995563,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"cba27cebe35c2f39634f031301bd1605","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU2328871848.SGD","600276","BK0060","HSTECH","LU0405327494.USD","HSCEI","BK0188","YANG","LU1064131003.USD","BK0196","BK0239","LU0405327148.USD","BK0183","07226","06978","BK1574","LU1328615791.USD","LU2148510915.USD","LU1969619763.USD","01276","159992","LU2488822045.USD","BK0028","BK0012","BK4614","LU1064130708.USD","BK1161"],"gpt_icon":0},{"id":"2537990180","title":"恆瑞醫藥在港上市敲鐘，全球化拓展加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2537990180","media":"国际金融报","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537990180?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:46","pubTimestamp":1747993580,"startTime":"0","endTime":"0","summary":"公开资料显示，恒瑞医药创立于1970年，于2000年在上海证券交易所上市。恒瑞医药此次全球发售H股总数为224,519,800股，发行价44.05港元，为发行区间上限定价。在赴港上市的过程中，国际化投资者的热烈响应反映出对公司未来国际化收入潜力的信心。此次赴港上市是恒瑞医药出海战略的关键一步，依托港股对接国际资本市场，可提升公司在全球的品牌影响力、强化公司国际化制药集团定位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505231749459500493f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505231749459500493f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276"],"gpt_icon":1},{"id":"2537134751","title":"中信證券助力恆瑞醫藥完成2021年以來港股醫療健康行業最大規模IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2537134751","media":"中信里昂 CITIC CLSA","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537134751?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:45","pubTimestamp":1747993530,"startTime":"0","endTime":"0","summary":"2021年以来最大的医疗健康行业港股IPO中信证券发挥综合服务优势助力圆满完成恒瑞医药本次IPO是2021年以来医疗健康行业融资规模最大的港股IPO项目，拥有由全球顶级投资机构组成的豪华基石阵容；在簿记过程中更是吸引数百家国内外知名机构下单，涵盖国际长线、主权基金、多策略基金、中资长线等多类型优质投资者；最终香港公开发售部分录得454.85倍认购，国际配售部分获17.09倍认购，受到市场广泛关注及参与。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523212951a6ea5d81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523212951a6ea5d81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0183","LU0405327148.USD","LU1997245094.SGD","LU2488822045.USD","BK0239","159557","LU0405327494.USD","BK0188","LU1064130708.USD","BK0196","LU1064131003.USD","600030","01276","LU1997245177.USD","LU1997244956.HKD","BK0028","BK0276","LU1328615791.USD","LU2495084118.USD","BK0012","LU2289578879.USD","BK0060","LU2328871848.SGD","LU1655091616.SGD","600276","LU1969619763.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2537215668","title":"漲30%，恆瑞醫藥登陸港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2537215668","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537215668?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:39","pubTimestamp":1747993140,"startTime":"0","endTime":"0","summary":"恒瑞医药在港交所上市，募资98.9亿港元，用于研发、扩建及营运等，吸引GIC、高瓴等基石投资者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505240113289500a217&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505240113289500a217&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1328615791.USD","BK0196","BK0028","600276","LU2148510915.USD","LU2488822045.USD","01276","BK0239","LU0405327148.USD","LU0405327494.USD","LU1064130708.USD","LU1969619763.USD","LU2328871848.SGD","LU1064131003.USD","BK0188","BK0060","BK0012","BK0183"],"gpt_icon":0},{"id":"2537991182","title":"恆瑞醫藥H股5月23日掛牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2537991182","media":"贝果财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537991182?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:32","pubTimestamp":1747992720,"startTime":"0","endTime":"0","summary":"【#恒瑞医药H股5月23日挂牌上市#】5月23日，恒瑞医药正式登陆港交所，成为今年最大的医药IPO。截至收盘，恒瑞医药股价上涨25.2%，报55.15港元/股，总市值超3600亿元，不含手续费一手（200股）赚2220港元。#港股# 今年以来，医药板块呈现出回暖态势，港股与A股相关指数均有不同程度上涨，其中创新药被视为价值洼地。目前，得益于国内医药政策、资本市场融资政策等对创新药研发的支持，国产创新药加速发展。据统计，科创板生物医药企业已推动27款国产1类创新药获批上市，16款产品的32项适应症被纳入突破性治疗品种。（财经新媒体）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-23/doc-inexpzxx0666852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2488822045.USD","BK0239","LU1064130708.USD","BK0188","LU1328615791.USD","LU0405327148.USD","LU2328871848.SGD","LU0405327494.USD","01276","600276","BK0060","LU1064131003.USD","LU1969619763.USD","BK0196","BK0012","BK0183","BK0028","LU2148510915.USD"],"gpt_icon":0},{"id":"2537158939","title":"【矚目】恆瑞拿下重磅1類新藥，超600億市場波瀾再起","url":"https://stock-news.laohu8.com/highlight/detail?id=2537158939","media":"米内网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537158939?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:20","pubTimestamp":1747992022,"startTime":"0","endTime":"0","summary":"精彩内容5月22日，国家药监局官网显示，恒瑞医药子公司山东盛迪医药申报的1类创新药瑞格列汀二甲双胍片/获批上市。米内网数据显示，糖尿病用药（化+生）在近年中国三大终端六大市场销售规模均超过600亿元，2024年同比增长7.22%。截至目前，恒瑞医药在瑞格列汀二甲双胍片相关项目累计研发投入约7660万元。此外，舒地胰岛素注射液、HR20031片(Ⅰ)/(Ⅱ)2款产品报产在审。恒瑞医药糖尿病用药产品报产在审情况来源：米内网中国申报进度数据库","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523231411a6ea72f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523231411a6ea72f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","LU0405327494.USD","LU2328871848.SGD","BK0028","LU1969619763.USD","LU1328615791.USD","LU1064131003.USD","01276","BK0183","LU2488822045.USD","BK0196","BK0239","600276","BK0012","BK0060","LU2148510915.USD","LU1064130708.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2537184675","title":"恆瑞新起點","url":"https://stock-news.laohu8.com/highlight/detail?id=2537184675","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537184675?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:18","pubTimestamp":1747991927,"startTime":"0","endTime":"0","summary":"恒瑞医药长期占据A股“医药一哥”宝座，本次登陆港交所，是恒瑞医药迈向国际化的新起点。创新药业务，在国家医保谈判的控费大环境下，恒瑞医药虽有十几款创新药上市，然而2024年创新药收入不过138.92亿元，占营收比重从2022年的38.1%增至2024年的49.64%，仍未过半。恒瑞医药在招股书中明确，此次募资将重点用于研发计划、中国和海外市场建设新的生产和研发设施及其他用途。而恒瑞医药已在代谢性疾病领域持续探索创新多年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523172542a6ea1155&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523172542a6ea1155&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1328615791.USD","LU2488822045.USD","BK0239","BK0196","BK0183","LU1064131003.USD","LU1969619763.USD","LU1064130708.USD","LU2328871848.SGD","01276","BK0188","600276","BK0028","LU0405327148.USD","BK0060","BK0012","LU2148510915.USD","LU0405327494.USD"],"gpt_icon":0},{"id":"2537580151","title":"30CM暴漲！41萬股民哭暈，3600億元大白馬，徹底殺瘋了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2537580151","media":"萝卜投研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537580151?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:17","pubTimestamp":1747991860,"startTime":"0","endTime":"0","summary":"恒瑞医药港股上市首日，盘中一度大涨超30%，最新总市值达3960亿港元。2022年至2024年，恒瑞医药收入分别为212.75亿、228.2亿以及279.85亿；利润分别为38.15亿、42.78亿以及63.37亿，2024年净利增长48%。而2024年，恒瑞医药创新药收入占比首次超过仿制药，成为第一大收入来源，使得资本又一次从恒瑞医药进行了重估。据统计，恒瑞医药当前累计达成14笔创新药对外授权合作。今年3月，公司与默沙东达成的HRS-5346授权协议，首付款2亿美元叠加里程碑款项，最高可达19.7亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523232509a489dcbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523232509a489dcbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","LU1969619763.USD","LU1064130708.USD","LU1064131003.USD","BK0183","BK0028","BK0196","LU1328615791.USD","LU2488822045.USD","LU2148510915.USD","01276","LU0405327148.USD","600276","LU2328871848.SGD","BK0239","LU0405327494.USD","BK0012","BK0060"],"gpt_icon":0},{"id":"2537156681","title":"恆瑞創今年醫藥IPO紀錄，三生刷新對外授權首付款紀錄，麗珠“出手”越南，中國醫藥出海大潮開啓？","url":"https://stock-news.laohu8.com/highlight/detail?id=2537156681","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537156681?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 17:02","pubTimestamp":1747990920,"startTime":"0","endTime":"0","summary":"恒瑞医药港股上市创今年医药IPO纪录，三生制药刷新对外授权首付款纪录，丽珠医药收购越南公司，中国创新药企国际化步伐加速，资本市场支持未盈利科技企业上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505240109249500a167&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505240109249500a167&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0196","600056","BK0250","LU1064131003.USD","BK0175","BK0012","BK0185","LU2328871848.SGD","01276","BK0010","BK0028","BK0082","159938","LU1969619763.USD","LU0405327494.USD","LU1328615791.USD","BK0239","LU1064130708.USD","BK0188","600276","BK0060","LU2148510915.USD","LU2488822045.USD","LU0405327148.USD","BK0183"],"gpt_icon":0},{"id":"2537866881","title":"3500億市值藥企赴港敲鐘，折價發行半日股價漲超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537866881","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537866881?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 16:57","pubTimestamp":1747990645,"startTime":"0","endTime":"0","summary":"投资时间网、标点财经研究员注意到，恒瑞医药在此次上市前获得资本市场热捧，5月22日暗盘交易已大涨超30%。今天开盘后，恒瑞医药股价一度上涨超37%，随后有所回落。据悉，恒瑞医药此次IPO全球发售2.25亿股，其中香港公开发售占21.50%，获454.85倍认购；国际发售占78.50%，获17.09倍认购。近年来，恒瑞医药持续加大研发投入，2022年至2024年的研发费用分别为48.87亿元、49.54亿元和65.83亿元，分别占当期公司总收入的23.0%、21.7%和23.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523170036976312f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523170036976312f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","HSTECH"],"gpt_icon":1},{"id":"2537868081","title":"恆瑞醫藥港股上市首日漲25.2% 募資淨額97.47億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537868081","media":"中国经济网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537868081?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 16:55","pubTimestamp":1747990558,"startTime":"0","endTime":"0","summary":"中国经济网北京5月23日讯江苏恒瑞医药股份有限公司（简称“恒瑞医药”，01276.HK）今日在港交所上市。截至收盘，该股收报55.15港元，涨幅25.20%。最终发售价及配发结果公告显示，恒瑞医药全球发售项下的发售股份数目为224,519,800股H股（视乎超额配股权行使与否而定）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505233413150132.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505233413150132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HSTECH","YANG","01276","BK4614","HSCEI"],"gpt_icon":1},{"id":"2537185050","title":"創新藥收入持續提升 恆瑞醫藥登陸港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2537185050","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537185050?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 16:55","pubTimestamp":1747990539,"startTime":"0","endTime":"0","summary":"5月23日，恒瑞医药（01276.HK）正式登陆港交所，实现“A+H”两地上市。上市首日的恒瑞医药高开29.4%，随后高开高走大涨超32%。据公司5月15日的公告显示，恒瑞医药拟全球发售224,519,800股H股（假设无发售量调整权及超额配股权行使），中国香港发售股份1234.86万股，国际发售股份约2.12亿股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505233413150751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","06978","01276"],"gpt_icon":1},{"id":"2537185013","title":"港股近五年最大醫藥IPO來了！恆瑞醫藥上市首日收漲超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537185013","media":"新华财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537185013?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 16:53","pubTimestamp":1747990409,"startTime":"0","endTime":"0","summary":"新华财经北京5月23日电（王媛媛）5月23日，A股医药巨头恒瑞医药正式登陆港交所。早盘，恒瑞医药高开29.4%，报57港元／股，其发行价为44.05港元／股。开盘后，恒瑞医药涨幅一度超过37%，随后全天在高位运行，截至收盘，恒瑞医药涨幅约25%，总市值3642亿元。同时，创新药沪深港ETF（517110）今日同样表现较好，盘中一度涨超2%，午后涨幅回落至0.5%附近。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505233413150542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","YANG","BK4614","BK1515","HSCEI","HSTECH","BK1574","09939","01276"],"gpt_icon":1},{"id":"2537186507","title":"恆瑞醫藥在港上市，首日開盤價較發行價上漲29.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537186507","media":"银柿财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537186507?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 16:49","pubTimestamp":1747990148,"startTime":"0","endTime":"0","summary":"恒瑞医药此次全球发售H股总数为224,519,800股，发行价44.05港元，为发行区间上限定价。回顾上市历程，2025年1月，恒瑞医药正式公告递表消息，历时4个多月后正式上市。港股上市开盘即高开，开盘价57港元/股，较发行价上涨29.4%；当日报收55.15港元/股，涨幅25.2%。A股恒瑞医药近一周多以来涨幅明显，5月13日到22日的8个交易日间涨9.72%，23日有所回调，当日报收54.5元/股，跌1.62%。此番恒瑞医药赴港上市时点正逢港股和A股创新药概念重获市场关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523165143a6ea0370&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523165143a6ea0370&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276"],"gpt_icon":1},{"id":"1100549993","title":"港股綜述｜恆瑞醫藥首日飆漲25%，Mirxes漲28%；阿里影業漲超8%，港股三大股指衝高回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1100549993","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100549993?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 16:42","pubTimestamp":1747989772,"startTime":"0","endTime":"0","summary":"个股方面：“A+H药企龙头”恒瑞医药、“新加坡微小核糖核酸技术公司”Mirxes两只新股今日登陆港交所，分别收涨25.2%、28.76%。$中国卫生集团$今日复牌一度飙升超1.7倍，最终收涨110.71%，公司折让28.6%配股引入新投资者。阿里影业涨超8%，公司拟更名为大麦娱乐，$花旗$称IP商品潜力尚未完全释放。A股行情A股市场冲高回落，三大指数午后集体跳水。截至收盘，沪指跌0.94%报3348点，深证成指跌0.85%，创业板指跌1.18%。","market":"us","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSI","02629","01276","01060"],"gpt_icon":1},{"id":"2537518529","title":"年內最強！最慘板塊終於熬出頭了","url":"https://stock-news.laohu8.com/highlight/detail?id=2537518529","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537518529?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 16:42","pubTimestamp":1747989760,"startTime":"0","endTime":"0","summary":"今年最热之一","market":"hk","thumbnail":"https://img3.gelonghui.com/cdb37-3a325ea1-9192-408c-b464-6354e6e75555.png?guru_height=601&guru_width=867","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/cdb37-3a325ea1-9192-408c-b464-6354e6e75555.png?guru_height=601&guru_width=867"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2225897","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0060","LU1969619763.USD","LU1064131003.USD","LU2488822045.USD","BK0012","159892","BK4614","LU1328615791.USD","HSTECH","600276","LU1064130708.USD","01276","BK0028","BK0196","BK1161","BK0239","LU0405327148.USD","LU0405327494.USD","BK1574","LU2328871848.SGD","LU2148510915.USD","YANG","HSCEI","BK0183","06978","BK0188"],"gpt_icon":1}],"pageSize":20,"totalPage":11,"pageCount":2,"totalSize":209,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.4091,"hold":0.2273,"sell":0.0455,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4091,"analysts":22,"updateTime":1743523200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-05-23","current":52.570963,"percent":0,"low":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"high":53.632028,"avg":53.101495,"sd":0.530532,"marketCap":390693388207.53},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53}],"updateTime":1748171518645}}}